Prescription Trends and Clinical Decision‐Making in Neuropathic Pain Pharmacological Treatment: Results From a Cross‐Sectional Survey by the Spanish Pain Society
European Journal of Pain · 2026-03 · 30 (3)
DOI: 10.1002/ejp.70246 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pain, online erschienen am 10.03.2026. Verfasst von Miguel Á Huerta und 17 weiteren Autor:innen. Beteiligte Einrichtung: Neuropathic Pain Working Group, Spanish Society of Pain (GTDN-SED), Madrid, Spain. Hauptthemen laut MEDLINE: Neuralgia, Analgesics, Practice Patterns, Physicians', Clinical Decision-Making. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Neuropathic pain (NP) is a complex chronic condition with limited therapeutic effectiveness. Despite multiple drug classes and international guidelines, real‐world adherence remains inconsistent, and data on prescribing practices among pain specialists is scarce.
Methods
We conducted a nationwide cross‐sectional survey among members of the Spanish Pain Society in May 2025. A structured 62‐item questionnaire assessed prescribing habits, decision‐making criteria, guideline adherence, dosage patterns, and the recognition and management of tolerance. Sociodemographic and professional data were also collected.
Results
A total of 220 pain specialists (52% female) completed the survey; 28% had over 20 years of clinical experience. Satisfaction with current pharmacological options was modest, with 52% reporting dissatisfaction or indifference. Prescribing was mainly guided by clinical experience (43%) and guideline recommendations (36%). Gabapentin (45%) and pregabalin (40%) were the most frequent first‐line choices, followed by tricyclic antidepressants (amitriptyline; 9%), duloxetine (5%) and venlafaxine (1%). Tramadol dominated second‐line use (65%), followed by capsaicin (22%) or lidocaine (5%) patches. Half of the participants reported tolerance, typically after 3–12 months, managed mainly by dose escalation or switching drug classes. Dosage practices for gabapentinoids and antidepressants showed marked heterogeneity, with frequent deviations from recommended titration protocols.
Conclusions
NP management in Spain shows variability and partial alignment with international guidelines. Gabapentinoids, tricyclic antidepressants and duloxetine remain preferred treatments, but reliance on personal experience and awareness of tolerance hinder evidence‐based practice. Quantifying Spanish pain specialists' views on tolerance supports calls for national consensus, better dosing education and further research to harmonise care and improve outcomes. Significance This nationwide survey provides the first systematic assessment of neuropathic pain management in Spain, revealing marked variability, only partial adherence to international guidelines, and persistent reliance on clinical experience over evidence. It confirms gabapentinoids, tricyclic antidepressants and duloxetine as preferred treatments, identifies continued tramadol use despite conflicting recommendations, and quantifies for the first time clinicians' perception and management of tolerance. These findings fill a major evidence gap and directly inform future national consensus, educational initiatives and clinical practice improvement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuropathic Pain Working Group, Spanish Society of Pain (GTDN-SED), Madrid, Spain.
- Department of Pharmacology, University of Granada, Granada, Spain.
- Biosanitary Research Institute ibs.GRANADA, Beiro (Granada), Spain.
- Pain Unit, Service of Anaesthesiology and Resuscitation, University Hospital Complex of Vigo, Galician Healthcare Service (SERGAS), Vigo, Pontevedra, Spain.
- Area of Pharmacology, Nutrition and Bromatology, Department of Basic Health Sciences, Unidad Asociada de I+D+i al Instituto de Química Médica (IQM) CSIC-URJC, Universidad Rey Juan Carlos, Alcorcón (Madrid), Spain.
- High Performance Experimental Pharmacology Research Group, Universidad Rey Juan Carlos (PHARMAKOM), Alcorcón (Madrid), Spain.
ORCID-Profile: Miguel Á Huerta, Mónica Mayo-Moldes, Miguel M Garcia, Beliu García-Parra, Yolanda López-Tofiño, Nancy Paniagua, Mar Hernández-Secorún, Julian Taylor, Enrique Verdú, José A Valencia, Silvia Pico, Clara Díaz-Alejo, Masahito Katsuki, Ancor Serrano-Afonso, M Carmen Ruiz-Cantero
Zitieren
APA
Huerta, M. Á., Mayo-Moldes, M., Garcia, M. M., García-Parra, B., Matute, M., López-Tofiño, Y., Paniagua, N., Hernández-Secorún, M., Soler, D., Salmerón, M., Taylor, J., Verdú, E., Valencia, J. A., Pico, S., Díaz-Alejo, C., Katsuki, M., Serrano-Afonso, A., & Ruiz-Cantero, M. C. (2026). Prescription Trends and Clinical Decision‐Making in Neuropathic Pain Pharmacological Treatment: Results From a Cross‐Sectional Survey by the Spanish Pain Society. European Journal of Pain, 30(3). https://doi.org/10.1002/ejp.70246
Vancouver
Huerta MÁ, Mayo-Moldes M, Garcia MM, García-Parra B, Matute M, López-Tofiño Y, et al. Prescription Trends and Clinical Decision‐Making in Neuropathic Pain Pharmacological Treatment: Results From a Cross‐Sectional Survey by the Spanish Pain Society. European Journal of Pain. 2026;30(3). doi:10.1002/ejp.70246
BibTeX
@article{Huerta2026,
author = {Huerta, Miguel Á and Mayo-Moldes, Mónica and Garcia, Miguel M and García-Parra, Beliu and Matute, Mercè and López-Tofiño, Yolanda and Paniagua, Nancy and Hernández-Secorún, Mar and Soler, Dolors and Salmerón, Marcos and Taylor, Julian and Verdú, Enrique and Valencia, José A and Pico, Silvia and Díaz-Alejo, Clara and Katsuki, Masahito and Serrano-Afonso, Ancor and Ruiz-Cantero, M Carmen},
title = {Prescription Trends and Clinical Decision‐Making in Neuropathic Pain Pharmacological Treatment: Results From a Cross‐Sectional Survey by the Spanish Pain Society},
journal = {European Journal of Pain},
year = {2026},
volume = {30},
number = {3},
doi = {10.1002/ejp.70246}
}
EUVIMED